Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 7/20 | 0.47 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.40 |
| ▸ | GLS | O94925 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29850092 | 0.87 | NAMPT (0.49) | NAMPTCYP17A1MAPKAPK2PSMB8MAP4K4 | |
| SCHEMBL17247383 | 0.87 | MAPKAPK2 (0.53) | NAMPTCYP17A1MAPKAPK2PSMB8MAP4K4 | |
| SCHEMBL853159 | 0.87 | NAMPT (0.49) | NAMPTCYP17A1MAPKAPK2PSMB8MAP4K4 | |
| SCHEMBL14260617 | 0.86 | NAMPT (0.48) | NAMPTCYP17A1MAPKAPK2PSMB8MAP4K4 | |
| SCHEMBL16245958 | 0.84 | NAMPT (0.47) | NAMPTCYP17A1MAPKAPK2PSMB8MAP4K4 | |
| SCHEMBL4373897 | 0.84 | PTGDR2 (0.49) | NAMPTCYP17A1MAPKAPK2PSMB8MAP4K4 | |
| SCHEMBL16246250 | 0.83 | NAMPT (0.46) | NAMPTCYP17A1MAPKAPK2PSMB8MAP4K4 | |
| SCHEMBL13990400 | 0.83 | NAMPT (0.46) | NAMPTCYP17A1MAPKAPK2PSMB8MAP4K4 | |
| SCHEMBL13141081 | 0.83 | NAMPT (0.46) | NAMPTCYP17A1MAPKAPK2PSMB8MAP4K4 | |
| SCHEMBL28256620 | 0.83 | NAMPT (0.46) | NAMPTCYP17A1MAPKAPK2PSMB8MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858912-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230133845-A1 | NOVEL HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-7868188-B2 | 5-heteroaryl thiazoles and their use as PI3K inhibitors | ASTRAZENECA AB (SE) | 2011-01-11 | — | — | US | disclosed |
| EP-1841763-B1 | 5-HETEROARYL THIAZOLES AND THEIR USE AS PI3K INHIBITORS | ASTRAZENECA AB (SE) | 2010-06-30 | — | — | EP | disclosed |
| US-20080132502-A1 | 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858912-B2 | Heterocyclic compounds | F12, C1R, MRPL21 | NAMPT 1241/4885CYP17A1 1767/4885MAPKAPK2 4701/4885 |
| US-20230133845-A1 | NOVEL HETEROCYCLIC COMPOUNDS | F12, PM20D2, XDH | NAMPT 1704/4885CYP17A1 1788/4885MAPKAPK2 4682/4885 |
| US-20080132502-A1 | 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors | MTOR, PIK3R5, PIK3CA | NAMPT 1189/4885CYP17A1 419/4885MAPKAPK2 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.